Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...
FierceBiotech12h
Gilead's Daniel O'Day relishes Dietmar Berger reunion as cancer specialist agrees to join from Sanofi
Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Sanofi's Tolebrutinib Gets FDA Breakthrough Therapy Designation For NrSPMS
French drug major Sanofi (SNY) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy ...
Novavax advances growth strategy through partnership with Sanofi
Novavax (NVAX) announced progress in Q4 advancing its corporate growth strategy through its partnership with Sanofi (SNY). The company has ...
The Pharma Letter8h
FDA status for Sanofi’s tolebrutinib in non-relapsing secondary progressive MS
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of ...
RFK Jr. ally filed petition to revoke FDA approval for polio vaccine
Aaron Siri - a lawyer with a history of seeking to expand exemptions to vaccines- asked the FDA to suspend or withdraw ...
Gilead Sciences Names Sanofi's Berger as Next Chief Medical Officer
Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey.
Stocktwits on MSN6h
Novavax Nabs $50M From First Sanofi Partnership Milestone: Retail Optimism Climbs
The company announced it achieved the first milestone under its Sanofi partnership, earning a $50 million payment for ...
What the Polio Vaccine Has Meant for Public Health
A lawyer working with Robert F. Kennedy Jr. has asked the F.D.A. to withdraw approval of the current shot because it hasn’t ...
Daily11h
USFDA grants Breakthrough Therapy designation to Sanofi tolebrutinib for non-relapsing secondary progressive multiple sclerosis
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
sanofi13h
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults ...